ENSC Stock Overview A clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Ensysce Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Ensysce Biosciences Historical stock prices Current Share Price US$8.10 52 Week High US$30.90 52 Week Low US$2.12 Beta 0.60 1 Month Change -17.65% 3 Month Change 67.60% 1 Year Change -48.08% 3 Year Change -99.96% 5 Year Change -99.98% Change since IPO -99.98%
Recent News & Updates
Price target increased by 515% to US$627 Dec 09
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split to Regain Compliance with Bid Price Requirement Dec 04
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 14
This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate Nov 14
Ensysce Biosciences Receives Positive Nasdaq Listing Determination Nov 07
Ensysce Biosciences, Inc., Annual General Meeting, Nov 21, 2024 Oct 08 See more updates
Price target increased by 515% to US$627 Dec 09
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split to Regain Compliance with Bid Price Requirement Dec 04
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 14
This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate Nov 14
Ensysce Biosciences Receives Positive Nasdaq Listing Determination Nov 07
Ensysce Biosciences, Inc., Annual General Meeting, Nov 21, 2024 Oct 08
Ensysce Biosciences, Inc. Submits Phase 3 Protocol to the FDA Sep 20
Price target decreased by 32% to US$9.05 Sep 01 Ensysce Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $1.669895 million. Aug 30
Ensysce Biosciences, Inc. Announces IRB Approval for Key MPAR Study Aug 28
Consensus revenue estimates decrease by 25%, EPS upgraded Aug 21
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 16
Consensus revenue estimates decrease by 26%, EPS upgraded May 20
No longer forecast to breakeven May 15
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 13
Price target increased by 16% to US$13.50 Apr 09
Ensysce Biosciences Receives Notice from The Nasdaq Stock Market Regarding Non-Compliance with Nasdaq Listing Rule 5550(a)(2) Mar 30
Consensus EPS estimates fall by 32% Mar 22
Price target decreased by 16% to US$11.33 Mar 21
Forecast to breakeven in 2026 Mar 18
Full year 2023 earnings released Mar 15
Price target decreased by 13% to US$11.65 Feb 20
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript Feb 15
New minor risk - Profitability Feb 14
Price target decreased by 13% to US$11.65 Feb 14
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain Feb 01 Ensysce Biosciences, Inc. has filed a Follow-on Equity Offering. Jan 17
Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic Dec 15
New major risk - Share price stability Dec 01 Ensysce Biosciences, Inc. announced that it has received $1.7 million in funding Nov 29
Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq Nov 18
Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study Nov 17
Consensus revenue estimates decrease by 21%, EPS upgraded Nov 16
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 11 Ensysce Biosciences, Inc. announced that it expects to receive $1.7 million in funding Oct 25
Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study Sep 27
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies Sep 15
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 13
Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol Aug 09
Ensysce Biosciences, Inc., Annual General Meeting, Aug 24, 2023 Jul 15
Ensysce Biosciences Regains Compliance with the Equity Requirement in Nasdaq Listing Rule 5550(b)(1) Jun 14
Consensus EPS estimates upgraded to US$9.75 loss, revenue downgraded May 22
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 17 Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering. May 11
Consensus revenue estimates increase by 14% Apr 13
Price target decreased by 58% to US$29.40 Apr 12
Full year 2022 earnings: EPS and revenues miss analyst expectations Apr 02
Independent Chairman of the Board recently bought US$182k worth of stock Mar 03 Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $3.000002 million. Feb 08
Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq Feb 01
Ensysce Biosciences, Inc. Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study Jan 26
Ensysce Biosciences, Inc. Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial Jan 05
Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection Dec 21
Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq Dec 17
Consensus forecasts updated Dec 10 Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $4.06 million. Dec 09
Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $4.06 million. Dec 08
Ensysce Biosciences Inc. Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A Dec 06
Consensus revenue estimates fall by 33% Nov 21
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 18
Price target increased to US$240 Nov 17
High number of new directors Nov 16 Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for Pf614
Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, A TAAP Abuse-Deterrent Oxycodone Extended-Release Product Nov 01
Ensysce Biosciences, Inc. Announces First Subjects Dosed in Second Human Abuse Potential Study Oct 29
Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR Sep 23
Ensysce Biosciences, Inc. Announces Chief Medical Officer Changes Sep 17
Ensysce Biosciences and Quotient Sciences Announce A Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, A Novel Opioid Designed to Prevent Abuse and Overdose Sep 01
Consensus forecasts updated Aug 19
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 12 Ensysce Biosciences, Inc. announced that it has received $8 million in funding Aug 10
Independent Chairman of the Board notifies of intention to sell stock Jul 08 Shareholder Returns ENSC US Biotechs US Market 7D 44.1% -5.6% -3.5% 1Y -48.1% -1.5% 22.1%
See full shareholder returns
Return vs Industry: ENSC underperformed the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: ENSC underperformed the US Market which returned 22.1% over the past year.
Price Volatility Is ENSC's price volatile compared to industry and market? ENSC volatility ENSC Average Weekly Movement 53.8% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ENSC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ENSC's weekly volatility has increased from 30% to 54% over the past year.
About the Company Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis.
Show more Ensysce Biosciences, Inc. Fundamentals Summary How do Ensysce Biosciences's earnings and revenue compare to its market cap? ENSC fundamental statistics Market cap US$10.37m Earnings (TTM ) -US$7.93m Revenue (TTM ) US$4.42m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ENSC income statement (TTM ) Revenue US$4.42m Cost of Revenue US$5.65m Gross Profit -US$1.23m Other Expenses US$6.70m Earnings -US$7.93m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -6.07 Gross Margin -27.78% Net Profit Margin -179.29% Debt/Equity Ratio 5.9%
How did ENSC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 00:46 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ensysce Biosciences, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Hunter Diamond Diamond Equity Research LLC Bradley Sorensen Zacks Small-Cap Research
Show 0 more analysts 
